Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.40 |
| ▸ | ITGAL | P20701 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88481 | 1.00 | ECE1 (0.46) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL30406637 | 1.00 | ECE1 (0.46) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL28035646 | 0.88 | ECE1 (0.39) | ECE1ITGB2ICAM1ITGALCA2 | |
| Phenol SCHEMBL27348628 | 0.85 | ALDH1A1 (0.46) | ECE1ITGB2ICAM1ITGALCA2 | |
| Phenol SCHEMBL28342610 | 0.85 | ALDH1A1 (0.46) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL3856802 | 0.84 | ECE1 (0.42) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL7034111 | 0.84 | ECE1 (0.42) | ECE1ITGB2ICAM1ITGALCA2 | |
| Benzene SCHEMBL28092853 | 0.83 | ECE1 (0.39) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL1688082 | 0.83 | ECE1 (0.40) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL30089038 | 0.83 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 665 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115297958-A | Microcapsules coated with polysuccinimide derivatives | 弗门尼舍有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-104045698-B | Polypeptide, polypeptide derivative, medicinal salt of polypeptide and medicinal composition | 深圳君圣泰生物技术有限公司 | 2019-04-16 | — | — | CN | claimed |
| EP-2341774-B1 | TREATMENT OF NEUROBLASTOMA WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN | BELROSE PHARMA INC (US) | 2013-12-04 | — | — | EP | claimed |
| US-20120322717-A9 | Compounds and assays for controlling Wnt activity | ENZO BIOCHEM, INC. | 2012-12-20 | — | — | US | claimed |
| US-20100298200-A1 | Compounds and assays for controlling Wnt activity | LIU DAKAI | 2010-11-25 | — | — | US | claimed |
| JP-2010524472-A | — | — | 2010-07-22 | — | — | JP | claimed |
| EP-2147116-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | Enzon Pharmaceuticals, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2008131208-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-12600778-B2 | Rage antibodies, fragments and uses thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-04-14 | — | — | US | disclosed |
| US-12594342-B2 | Method of conjugation of Cys-mAbs | AMGEN INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260077054-A1 | COMBINATIONS OF ANTI-GIP ANTIBODIES AND INCRETINS AND USES THEREOF | HELICORE BIOPHARMA INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034235-A1 | METHOD OF CONJUGATION OF CYS-MABS | AMGEN INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001956-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | AMGEN INC. (US) | 2026-01-01 | — | — | US | disclosed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | disclosed |
| CN-1051769-C | Peptides | NOVATIS INC (CH) | 2000-04-26 | — | — | CN | disclosed |
| US-5622934-A | TREATING DIABETES MELLITUS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0672057-A1 | ANALOGS OF PTH | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| CN-1099801-A | Peptides | SANDOZ LTD (CH) | 1995-03-08 | — | — | CN | disclosed |
| WO-1994002510-A2 | ANALOGS OF PTH | SANDOZ LTD. (CH) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322717-A9 | Compounds and assays for controlling Wnt activity | WNT1, WNT3A, WNT3 | ECE1 3548/4885ITGB2 3089/4885ICAM1 3351/4885 |
| US-12594342-B2 | Method of conjugation of Cys-mAbs | TST, PTMS, TMT1A | ECE1 4675/4885ITGB2 140/4885ICAM1 1025/4885 |
| US-20260034235-A1 | METHOD OF CONJUGATION OF CYS-MABS | CBS, GCLC, PTMS | ECE1 4332/4885ITGB2 202/4885ICAM1 1028/4885 |
| US-20260001956-A1 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS | GIPR, GLP1R, IAPP | ECE1 4104/4885ITGB2 2192/4885ICAM1 314/4885 |
| US-20260077054-A1 | COMBINATIONS OF ANTI-GIP ANTIBODIES AND INCRETINS AND USES THEREOF | GIPR, GLP1R, GPR119 | ECE1 3064/4885ITGB2 3153/4885ICAM1 393/4885 |
| US-20100298200-A1 | Compounds and assays for controlling Wnt activity | WNT1, WNT3A, WNT3 | ECE1 3548/4885ITGB2 3089/4885ICAM1 3351/4885 |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ADA, CDA, DCTD | ECE1 2396/4885ITGB2 4510/4885ICAM1 3967/4885 |
| US-12600778-B2 | Rage antibodies, fragments and uses thereof | IGSF11, FCGR1A, FCGR3B | ECE1 3901/4885ITGB2 68/4885ICAM1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.